Early relations with regulators key to solving innovation problem
This article was originally published in SRA
One of the most important contributions the pharmaceutical industry can make to improving innovation and reducing the chance of costly trials failing is to align itself earlier with key stakeholders, such as drug regulators and reimbursement bodies, Professor Stuart Walker, founder of CMR International Institute for Regulatory Science, told delegates at the 7th annual meeting of The Organisation for Professionals in Regulatory Affairs in London on 4-6 October.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.